Medincell: Half-Year Liquidity Contract Statement

Regulatory News:

Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2025:

• 5 000 shares

• 1 145 177

Over the period from 01/01/2025 to 30/06/2025, a total of

	Number of executions	Number of shares	Traded volume in EUR
Buy side	11,807	759,363	11,677,812.97
Sell side	11,343	758,413	11,671,875.50

It should be noted that Medincell increased the funds allocated to the liquidity contract by €600,000 on 11 April 2025.

At the time of its implementation on September 11, 2024, the following resources were included in the liquidity account:

• 8 824 shares
• 466 568.49

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY (BEPO technology is licensed to Teva under the name SteadyTeq). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.
UZEDY and SteadyTeq are registered trademarks of Teva Pharmaceuticals.
www.medincell.com

This press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company's control and to the Company's financial capabilities.

These statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as "objective", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "should", "could" and other words or expressions of similar meaning or used in the negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control which may cause actual results, performance or achievements of the Company to differ materially from those anticipated or implied by such statements.

A list and description of such risks, hazards and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including in the Company's document de base, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in documents and reports to be published subsequently by the Company. Furthermore, these forward-looking statements only apply as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements, nor to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if new information becomes available. The Company's updating of one or more forward-looking statements does not imply that it will or will not update these or any other forward-looking statements.

This press release is published for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, particularly in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not intended to address the investment objectives, financial situation or specific needs of any particular recipient. It should not be relied upon as a substitute for the exercise of your own judgement. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.

Appendices Rothschild Martin Maurel from 01/01/2025 to 30/06/2025

DATE	NB_BUY	NB_SALE	QTE_BUY	QTE_SALE	CAPITAL_BUY	CAPITAL_SALE
02/01/2025	89	132	1,607	5,257	26,949.39	89,631.85
03/01/2025	65	61	2,170	2,570	38,343.90	45,900.20
06/01/2025	111	85	3,509	2,609	63,758.53	47,562.07
07/01/2025	135	116	7,131	4,281	126,432.63	75,688.08
08/01/2025	63	66	3,356	3,356	57,924.56	58,025.24
09/01/2025	86	52	3,965	1,715	67,167.10	29,103.55
10/01/2025	70	43	2,336	1,336	39,011.20	22,391.36
13/01/2025	110	76	2,580	2,830	41,899.20	45,987.50
14/01/2025	50	51	1,848	1,848	30,196.32	30,362.64
15/01/2025	57	55	1,708	1,708	27,891.64	28,011.20
16/01/2025	31	51	2,238	3,238	36,277.98	52,585.12
17/01/2025	42	51	1,063	1,813	17,199.34	29,424.99
20/01/2025	47	32	1,971	1,971	32,028.75	32,068.17
21/01/2025	243	133	7,060	7,560	113,736.60	128,822.40
22/01/2025	48	75	1,456	2,706	23,179.52	43,323.06
23/01/2025	59	53	2,014	2,264	31,962.18	36,020.24
24/01/2025	44	98	1,850	2,810	29,507.50	45,044.30
27/01/2025	47	54	1,495	2,535	23,979.80	40,990.95
28/01/2025	61	135	555	1,555	9,301.80	25,828.55
29/01/2025	254	161	16,266	10,766	269,852.94	177,208.36
30/01/2025	226	230	16,770	16,520	259,767.30	256,060.00
31/01/2025	51	96	1,340	3,188	21,064.80	50,211.00
01/2025	1,989	1,906	84,288	84,436	1,387,432.98	1,390,250.83
03/02/2025	45	95	2,511	2,413	39,046.05	37,811.71
04/02/2025	48	47	2,065	2,065	32,895.45	32,978.05
05/02/2025	45	59	1,100	5,100	17,644.00	82,263.00
06/02/2025	41	39	1,826	1,826	29,928.14	29,946.40
07/02/2025	82	31	3,387	887	54,632.31	14,227.48
10/02/2025	161	69	4,812	2,062	74,537.88	32,167.20
11/02/2025	49	62	3,412	2,512	51,760.04	38,132.16
12/02/2025	52	38	1,643	1,793	24,743.58	27,038.44
13/02/2025	92	80	3,027	1,527	45,072.03	22,843.92
14/02/2025	156	160	4,414	3,414	63,164.34	48,547.08
17/02/2025	91	128	2,886	4,886	41,183.22	69,967.52
18/02/2025	144	95	3,940	3,403	55,238.80	47,744.09
19/02/2025	243	265	12,992	11,529	177,210.88	157,370.85
20/02/2025	245	126	3,818	4,318	52,039.34	59,070.24
21/02/2025	96	92	2,295	2,372	31,212.00	32,354.08
24/02/2025	78	54	1,618	1,541	22,020.98	21,065.47
25/02/2025	125	79	3,641	2,141	48,388.89	28,432.48
26/02/2025	240	295	6,989	11,489	95,819.19	160,156.66
27/02/2025	172	119	4,575	4,075	65,422.50	58,476.25
28/02/2025	110	109	2,625	2,625	37,170.00	37,511.25
02/2025	2,315	2,042	73,576	71,978	1,059,129.62	1,038,104.33
03/03/2025	80	110	832	2,532	11,964.16	36,435.48
04/03/2025	174	129	6,650	4,450	94,762.50	63,991.00
05/03/2025	117	266	8,281	11,081	119,163.59	159,677.21
06/03/2025	92	62	3,934	2,134	56,020.16	30,537.54
07/03/2025	122	153	8,000	7,000	112,320.00	98,280.00
10/03/2025	105	100	10,000	8,000	137,800.00	110,640.00
11/03/2025	84	77	3,416	2,156	46,491.76	29,450.96
12/03/2025	34	96	1,951	8,560	27,040.86	118,641.60
13/03/2025	106	94	7,706	5,757	107,421.64	80,425.29
14/03/2025	81	60	7,716	5,016	107,406.72	70,324.32
17/03/2025	71	114	7,879	10,921	109,518.10	152,020.32
18/03/2025	64	78	11,612	14,940	165,819.36	213,940.80
19/03/2025	91	112	11,437	11,808	166,865.83	172,396.80
20/03/2025	42	46	5,941	6,000	86,916.83	87,900.00
21/03/2025	71	87	9,902	9,152	147,935.88	137,005.44
24/03/2025	88	30	9,351	5,001	140,171.49	75,015.00
25/03/2025	67	56	4,661	3,961	69,029.41	58,662.41
26/03/2025	25	73	4,004	7,003	59,979.92	104,904.94
27/03/2025	67	45	6,457	4,558	96,467.58	68,005.36
28/03/2025	52	65	2,768	6,668	41,298.56	99,753.28
31/03/2025	91	30	7,061	1,361	102,808.16	20,006.70
03/2025	1,724	1,883	139,559	138,059	2,007,202.51	1,988,014.45
01/04/2025	106	93	8,067	6,567	115,922.79	94,433.46
02/04/2025	84	103	6,275	7,275	88,979.50	103,668.75
03/04/2025	55	27	4,332	3,422	61,124.52	48,318.64
04/04/2025	44	37	2,700	2,810	36,801.00	38,216.00
07/04/2025	2	3	150	570	1,923.00	7,341.60
08/04/2025	38	56	2,213	4,043	29,875.50	54,701.79
09/04/2025	63	50	4,913	3,463	64,311.17	45,053.63
10/04/2025	82	52	4,514	4,014	60,893.86	54,108.72
11/04/2025	74	50	4,515	3,690	58,559.55	47,970.00
14/04/2025	27	72	1,575	4,900	20,868.75	65,219.00
15/04/2025	31	57	1,525	4,025	21,106.00	55,625.50
16/04/2025	71	106	10,148	10,148	142,883.84	142,883.84
17/04/2025	54	66	4,844	4,844	68,300.40	68,494.16
22/04/2025	62	86	5,796	6,796	82,766.88	97,182.80
23/04/2025	121	110	10,326	10,326	150,966.12	151,172.64
24/04/2025	105	110	8,794	10,794	130,590.90	160,506.78
25/04/2025	115	58	9,039	4,039	136,217.73	60,544.61
28/04/2025	77	88	8,327	9,327	124,571.92	139,625.19
29/04/2025	96	107	10,750	10,750	160,927.50	161,250.00
30/04/2025	100	92	10,209	10,209	155,380.98	155,687.25
04/2025	1,407	1,423	119,012	122,012	1,712,971.91	1,752,004.36
02/05/2025	46	84	4,802	8,802	73,614.66	135,286.74
05/05/2025	102	103	10,750	9,500	164,045.00	145,350.00
06/05/2025	130	98	9,918	10,418	151,348.68	159,395.40
07/05/2025	110	92	7,131	7,881	109,104.30	120,894.54
08/05/2025	69	85	7,463	7,463	115,377.98	115,601.87
09/05/2025	48	36	4,721	4,721	73,553.18	73,600.39
12/05/2025	142	132	11,275	10,775	169,914.25	162,379.25
13/05/2025	113	92	11,500	10,000	174,455.00	151,700.00
14/05/2025	45	53	1,041	3,041	15,781.56	46,314.43
15/05/2025	69	13	5,050	1,050	77,063.00	15,960.00
16/05/2025	26	60	1,981	4,981	30,071.58	75,611.58
19/05/2025	52	44	3,166	4,166	49,421.26	65,072.92
20/05/2025	135	114	10,628	9,628	164,946.56	149,522.84
21/05/2025	50	80	3,791	4,791	59,025.87	74,979.15
22/05/2025	113	69	7,466	6,966	118,186.78	110,411.10
23/05/2025	145	141	5,722	5,722	91,609.22	92,410.30
26/05/2025	152	144	10,400	7,650	176,904.00	130,126.50
27/05/2025	85	125	8,270	10,020	140,259.20	170,039.40
28/05/2025	204	176	12,204	11,704	201,610.08	194,052.32
29/05/2025	145	123	12,000	9,357	199,680.00	155,887.62
30/05/2025	141	137	7,853	12,496	130,988.04	208,183.36
05/2025	2,122	2,001	157,132	161,132	2,486,960.20	2,552,779.71
02/06/2025	201	128	13,078	8,078	216,179.34	133,690.90
03/06/2025	193	156	10,185	10,657	164,589.60	173,282.82
04/06/2025	102	88	9,000	7,278	144,450.00	116,811.90
05/06/2025	89	139	5,250	11,500	84,892.50	186,415.00
06/06/2025	106	59	8,810	4,864	143,603.00	79,477.76
09/06/2025	83	76	6,319	6,223	101,040.81	99,692.46
10/06/2025	109	104	9,407	7,449	151,546.77	120,152.37
11/06/2025	134	73	10,000	4,000	158,300.00	63,360.00
12/06/2025	124	84	7,676	7,676	119,899.12	119,745.60
13/06/2025	158	128	9,356	9,356	144,363.08	144,456.64
16/06/2025	137	148	12,930	14,249	200,415.00	220,717.01
17/06/2025	99	53	11,926	3,624	181,871.50	55,048.56
18/06/2025	30	132	2,050	14,683	32,533.50	233,606.53
19/06/2025	64	103	5,849	9,699	95,748.13	159,548.55
20/06/2025	148	113	11,114	10,114	187,270.90	170,724.32
23/06/2025	101	84	12,940	9,440	223,991.40	163,123.20
24/06/2025	91	71	8,216	5,353	138,193.12	91,803.95
25/06/2025	58	123	4,825	8,688	81,397.75	147,087.84
26/06/2025	71	48	7,843	6,302	132,076.12	106,629.84
27/06/2025	67	106	9,209	12,750	155,816.28	216,495.00
30/06/2025	85	72	9,813	8,813	165,937.83	148,851.57
06/2025	2,250	2,088	185,796	180,796	3,024,115.75	2,950,721.82
S1/2025	11,807	11,343	759,363	758,413	11,677,812.97	11,671,875.50

View source version on businesswire.com: https://www.businesswire.com/news/home/20250724994231/en/

Contacts:

David Heuzé
Head of Corporate and Financial Communications, and ESG
[e-mail] [phone]

Grace Kim
Chief Strategy Officer, U.S. Finance
[e-mail] [phone]

Nicolas Mérigeau Arthur Rouillé
Media Relations
[e-mail] [phone]

Louis-Victor Delouvrier Alban Dufumier
Investor Relations France
[e-mail] [phone]